title: Drug-induced steatohepatitis.
abstract: Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease in the United States. The term NALFD was first used by Ludwig in 1980 to describe the presence of hepatic steatosis and steatohepatitis in a series of patients with no identifiable cause. Since then, our insight into the pathogenesis of NAFLD has expanded significantly. We now know that NAFLD is closely related to metabolic syndrome and chronic low-grade inflammation. In the following review, the authors summarize the current evidence about drugs that lead to hepatic steatosis and steatohepatitis and pathogenic mechanisms thereof.
authors.affiliation: Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Medical Center, Virginia Commonwealth University, MCV Box 980341, Richmond, VA 23298-0341, USA.
authors.forename: Vaishali
authors.initials: V
authors.lastname: Patel
authors.forename: Arun J
authors.initials: AJ
authors.lastname: Sanyal
mesh_terms: D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000209:etiology* / Q000378:metabolism / Q000628:therapy; D005234:Fatty Liver / Q000139:chemically induced* / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy; D006801:Humans
keywords: Drug-induced steatohepatitis; Microvesicular and macrovesicular steatosis; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis